High throughput screening for cyanovirin-N mimetics binding to HIV-1 gp41

Journal of Biomolecular Screening

Volumn 7, Issue 2, 2002, Pages 105-110

  Beutler, John A ^a   McMahon, James B ^a   Johnson, Tanya R ^a   O'Keefe, Barry R ^a   Buzzell, Randy A ^a   Robbins, Danielle ^a   Gardella, Roberta ^a   Wilson, Jennifer ^a   Boyd, Michael R ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOVIRIN N; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; LECTIN; MANNOSE; N ACETYLGLUCOSAMINE; NATURAL PRODUCT; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING COMPETITION; BIOASSAY; DRUG PROTEIN BINDING; DRUG SCREENING; FRACTIONATION; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ACETYLGLUCOSAMINE; ANTI-HIV AGENTS; BACTERIAL PROTEINS; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; BIOLOGICAL FACTORS; CARRIER PROTEINS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MANNOSE; MONOSACCHARIDES; PROTEIN BINDING; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036257229     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1089/10870570252906558     Document Type: Article

References (18)

1. Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41
2. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiledcoil pocket
3. Current evidence and future directions for targeting HIV entry: Therapeutic and prophylactic strategies
4. Human immunodeficiency virus type I entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
5. Novel compounds in preclinical/early clinical development for the treatment of HIV infections
6. HIV-1 entry-an expanding portal for drug discovery
7. Structural characterization of the human respiratory syncytial virus fusion protein core
8. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development
9. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium, Nostoc ellipsosporum
10. Multiple antiviral activities of cyanovirin-N: Blocking of gp120 interaction with CD4 and coreceptor, and inhibition of diverse enveloped viruses
11. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120
12. Analysis of the interaction between the virucidal protein cyanovirin-N and the HIV-1 envelope glycoproteins gp120.3 and gp41
13. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-dependent manner
14. Selective interactions of the HIV-inactivating protein, cyanovirin-N, with high-mannose oligosaccharides on gpl20 and other glycoproteins
15. Development of a cyanovirin-N/HIV-1 gpl20 binding assay for high throughput screening of natural products by time-resolved fluorescence
16. A semiautomated multiparameter approach for anti-HIV drug screening
17. Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii